Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome

Chemotherapy treatment of malignancy accounts for 1–2% of takotsubo syndrome (TS) triggers. Women comprise 60–70% of patients with chemotherapy-associated TS, a distinctly lower prevalence than the 90% female prevalence in TS overall. Fluorouracil is the most commonly reported TS-triggering chemothe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katelyn Storey, Scott W Sharkey
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/2ca97b83a2134bdabf38af4fc13a2ed4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2ca97b83a2134bdabf38af4fc13a2ed4
record_format	dspace
spelling	oai:doaj.org-article:2ca97b83a2134bdabf38af4fc13a2ed42021-12-04T16:02:18ZClinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome10.15420/usc.2019.10.11758-390X1758-3896https://doaj.org/article/2ca97b83a2134bdabf38af4fc13a2ed42020-02-01T00:00:00Zhttps://www.uscjournal.com/articles/Chemotherapy-Induced-Takotsubo-Syndromehttps://doaj.org/toc/1758-3896https://doaj.org/toc/1758-390XChemotherapy treatment of malignancy accounts for 1–2% of takotsubo syndrome (TS) triggers. Women comprise 60–70% of patients with chemotherapy-associated TS, a distinctly lower prevalence than the 90% female prevalence in TS overall. Fluorouracil is the most commonly reported TS-triggering chemotherapeutic agent, although this must be interpreted in the context of the frequency of worldwide use of this agent. The onset of TS relative to chemotherapy initiation is quite variable, ranging from the initial administration to subsequent chemotherapy cycles several weeks beyond initiation. Limited information suggests chemotherapy can be safely reinitiated once the patient has recovered from the initial TS event. Having a TS event in the setting of chemotherapy treatment for malignancy is associated with substantial mortality.Katelyn StoreyScott W SharkeyRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENUS Cardiology Review , Vol 13, Iss 2, Pp 74-82 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Katelyn Storey Scott W Sharkey Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
description	Chemotherapy treatment of malignancy accounts for 1–2% of takotsubo syndrome (TS) triggers. Women comprise 60–70% of patients with chemotherapy-associated TS, a distinctly lower prevalence than the 90% female prevalence in TS overall. Fluorouracil is the most commonly reported TS-triggering chemotherapeutic agent, although this must be interpreted in the context of the frequency of worldwide use of this agent. The onset of TS relative to chemotherapy initiation is quite variable, ranging from the initial administration to subsequent chemotherapy cycles several weeks beyond initiation. Limited information suggests chemotherapy can be safely reinitiated once the patient has recovered from the initial TS event. Having a TS event in the setting of chemotherapy treatment for malignancy is associated with substantial mortality.
format	article
author	Katelyn Storey Scott W Sharkey
author_facet	Katelyn Storey Scott W Sharkey
author_sort	Katelyn Storey
title	Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
title_short	Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
title_full	Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
title_fullStr	Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
title_full_unstemmed	Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
title_sort	clinical features and outcomes of patients with chemotherapy-induced takotsubo syndrome
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/2ca97b83a2134bdabf38af4fc13a2ed4
work_keys_str_mv	AT katelynstorey clinicalfeaturesandoutcomesofpatientswithchemotherapyinducedtakotsubosyndrome AT scottwsharkey clinicalfeaturesandoutcomesofpatientswithchemotherapyinducedtakotsubosyndrome
_version_	1718372723783106560

Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome

Ejemplares similares